Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib.
Steffen
S
Böhm
Dagmar
D
Hess
Silke
S
Gillessen
Michael
M
Brändle
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D015251:Epirubicin / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007191:Indazoles; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011743:Pyrimidines / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; D015251:Epirubicin; C516667:pazopanib